Monitor insider exercise behavior and future dilution; assess whether retention efforts correlate with future R&D or funding milestones.
VTGN drugs
VTGN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 14 $0.6000entry
- T+1 · 7mo ago +1.67%α +0.89% · $0.6100
- T+5 · 7mo ago +1.67%α +0.27% · $0.6100
- T+20 · 6mo ago +11.67%α +5.37% · $0.6700
- T+60 · 4mo ago −58.47%α −66.99% · $0.2492
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vistagen Therapeutics granted stock options to purchase 75,000 shares each to its CEO and other executive officers as retention awards. The options vest over two years and are intended to incentivize key leadership.
Key Facts
- Retention stock options granted to CEO Shawn K. Singh and four other executive officers.
- Each executive received options to purchase 75,000 shares of common stock.
- Options have an exercise price of $0.5358 per share and vest 25% every six months over two years.
- Awards were approved by the Compensation Committee on April 7, 2026, under the 2019 Omnibus Equity Incentive Plan.
Financial Impact
Dilutive impact of up to 375,000 new shares if all options are exercised; nominal expense recognition over two years based on fair value.
Risk Factors
- Potential shareholder dilution upon option exercise.
- Limited cash runway implications if future financing is needed to support ongoing operations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-024943 |
| Document: 0001628280-26-024943-index-headers.html | 0001628280-26-024943 |
| Document: 0001628280-26-024943-index.html | 0001628280-26-024943 |
| Document: 0001628280-26-024943.txt | 0001628280-26-024943 |
Track record
21 reports on VTGN
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +20.40% at T+5 after the Jun 11, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $0.1843 Now $0.1800 −2.33% settles Nov 24
- Nov 13, 20263d ago Press Release Neutral 5/10 Entry $0.1805 Now $0.1800 −0.28% settles Nov 23
- Nov 9, 20267d ago 8-K Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $0.1844 to $0.1843 Now $0.1800 −2.39% ▼ −0.05% +1.64% vs SPY
- Oct 30, 202617d ago 8-K Bearish 6/10 Entry $0.1675 to $0.1844 Now $0.1800 −7.46% ▼ −10.09% −10.01% vs SPY
- Oct 9, 20265w ago 8-K Neutral 3/10 Entry $0.2300 to $0.2000 Now $0.1800 −21.74% ▼ −13.04% −11.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 4/10 Entry $0.2700 to $0.2800 Now $0.1800 −33.33% ▲ +3.70% +3.93% vs SPY
- Sep 24, 20267w ago 8-K Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Sep 24, 20267w ago Press Release Neutral 4/10 Entry $0.2950 to $0.2826 Now $0.1800 −38.98% ▼ −4.20% −3.79% vs SPY
- Aug 14, 202613w ago 8-K Bearish 6/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers